Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance

Bekir Tanriover, Song Zhang, Malcolm MacConmara, Ang Gao, Burhaneddin Sandikci, Mehmet U S Ayvaci, Mutlu Mete, Demetra Tsapepas, Nilum Rajora, Prince Mohan, Ronak Lakhia, Christopher Y. Lu, Miguel Vazquez

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Background and objectives: Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in living donor renal transplantation (LRT). However, use of IL2-RA remains controversial in LRT with tacrolimus (TAC)/mycophenolic acid (MPA) with or without steroids. Design, setting, participants, & measurements: The Organ Procurement and Transplantation Network registry was studied for patients receiving LRT from 2000 to 2012 maintained on TAC/MPA at discharge (n=36,153) to compare effectiveness of IL2-RA to other induction options. The cohort was initially divided into two groups based on use of maintenance steroid at time of hospital discharge: steroid (n=25,996) versus no-steroid (n=10,157). Each group was further stratified into three categories according to commonly used antibody induction approach: IL2-RA, rabbit anti-thymocyte globulin (r-ATG), and no-induction in the steroid group versus IL2-RA, r-ATG and alemtuzumab in the no-steroid group. The main outcomes were the risk of acute rejection at 1 year and overall allograft failure (graft failure or death) post-transplantation through the end of follow-up. Propensity score-weighted regression analysis was used to minimize selection bias due to non-random assignment of induction therapies. Results: Multivariable logistic and Cox analysis adjusted for propensity score showed that outcomes in the steroid group were similar between no-induction (odds ratio [OR], 0.96; 95% confidence interval [95% CI], 0.86 to 1.08 for acute rejection; and hazard ratio [HR], 0.99; 95% CI, 0.90 to 1.08 for overall allograft failure) and IL2-RA categories. In the no-steroid group, odds of acute rejection with r-ATG (OR, 0.73; 95% CI, 0.59 to 0.90) and alemtuzumab (OR, 0.53; 95% CI, 0.42 to 0.67) were lower; however, overall allograft failure risk was higher with alemtuzumab (HR, 1.27; 95% CI, 1.03 to 1.56) but not with r-ATG (HR, 1.19; 95% CI, 0.97 to 1.45), compared with IL2-RA induction. Conclusions: Compared with no-induction therapy, IL2-RA induction was not associated with better outcomes when TAC/MPA/steroids were used in LRT recipients. r-ATG appears to be an acceptable and possibly the preferred induction alternative for IL2-RA in steroid-avoidance protocols.

Original languageEnglish (US)
Pages (from-to)1041-1049
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume10
Issue number6
DOIs
StatePublished - 2015

Keywords

  • Acute allograft rejection
  • Immunosuppression
  • Kidney transplantation

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Fingerprint Dive into the research topics of 'Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance'. Together they form a unique fingerprint.

  • Cite this